Acknowledgments

The author’s original work cited was supported in part by the U.S. Public Health Service, National Institutes of Health grants, including R37 DK27085, MO1 RR00036 (now UL1 RR24992), P60 DK20579, and T32 DK07120, and by research grants and a fellowship award from the American Diabetes Association. The author is grateful for the contributions of his mentors, collaborators, and colleagues; the efforts of the postdoctoral fellows who did the bulk of the work and made the work better by their conceptual input; and the skilled nursing, technical, dietary, and data management and statistical assistance of the staff of the Washington University General Clinical Research Center.

The author has served as a consultant to several pharmaceutical or medical device firms, including Amgen Inc., Bristol-Myers Squibb/AstraZeneca, Calibrium, Johnson & Johnson, Lilly/Boehringer-Ingelheim, MannKind Corp., Marcadia Biotech, Medtronic MiniMed Inc., Merck and Co., Pfizer, Novo Nordisk A/S, Takeda Pharmaceuticals North America, and TolerRx Inc.